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Diabetic vascular complications are among the leading causes of morbidity and mortality in diabetic patients. In the past, many 
studies have focused on the mechanisms of hyperglycemia-induced chronic vascular complications via the formation of toxic 
metabolites such as oxidative stress, advanced glycosylated end products, persistent activation of protein kinase C, and increased 
sorbitol concentrations. However, vascular complications result from imbalances caused by increases in systemic toxic metabo-
lites, such as those that occur under conditions of hyperglycemia and dyslipidemia, and by reductions in endogenous protective 
factors such as insulin, vascular endothelial growth factor, and platelet derived growth factor. This review outlines some of the 
evidence supporting the importance of enhancing endogenous regenerative factors.
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The vascular complications of diabetes mellitus affect many 
organ systems, including the retina, kidney, nerve, and cardio-
vascular system. These serious complications are the leading 
causes of mortality and morbidity in diabetic patients. 
  Diabetic vascular complications result from imbalances 
caused by increases in the toxic effects of systemic metabolic 
abnormalities such as hyperglycemia, dyslipidemia, and hyper-
tension, and reductions in the regenerative effects of endoge-
nous protective factors such as insulin, vascular endothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), 
nitric oxide (NO), and antioxidant enzymes (Fig. 1). In the 
past, many studies on the mechanisms of diabetic complica-
tions have focused on the mechanisms by which hyperglyce-
mia might lead to the chronic vascular complications via the 
formation of toxic metabolites such as oxidants and advanced 
glycosylated products. These mechanisms include increases in 
oxidative stress, persistent activation of protein kinase C (PKC) 
and other signaling pathways, increased sorbitol concentra-
tions through the aldose reductase pathway, the elevated for-
mation of advanced glycosylation end products, and increased 
flux through the hexosamine pathway [1]. However, few stud-
ies have evaluated the importance of endogenous protective 
factors or the inhibitory effects of hyperglycemia in neutraliz-
ing these protective factors during the initiation and progres-
sion of diabetic complications. This review outlines some of 
the evidence supporting the importance of preventing and de-
laying the progression of diabetic complications. Further, the 
lack of success in finding effective clinical therapeutics to neu-
tralize the toxic effects of hyperglycemia could be due to the 
need for enhancing protective factors. 
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  Hyperglycemia-induced cellular apoptosis is a common pa-
thology of many diabetic complications such as for retinal peri-
cytes, renal podocytes, and vascular endothelial cells. In the 
case of diabetic retinopathy, accelerated pericyte apoptosis is 
one of the earliest and most specific findings of diabetic com-
plications. Enge et al. [2] reported that PDGF-B or PDGF 
receptor-β knockout mice exhibited pericyte apoptosis and 
retinal microvascular abnormalities similar to the early stages 
of diabetic retinopathy, indicating that PDGF-B is a very im-
portant survival factor for retinal pericytes. However, the level 
of PDGF-B expression was observed to be elevated in diabetic 
state compared with that in non-diabetic animal [3]. Thus, it 
was not clear whether pericyte loss results from PDGF-B abun-
dance or PDGF-B resistance. Recently, Geraldes et al. [4] clear-
ly demonstrated that hyperglycemia induced a persistent acti-
vation of PKC-δ, which leads to PDGF resistance in the retina. 
Under normal glucose condition, PDGF-B stimulated DNA 
synthesis, inhibited cellular apoptosis, and increased p-AKT 
and p-ERK activation in retinal pericytes. However, PDGF-in-
duced activation of p-AKT and p-ERK signaling was blunted 
by hyperglycemic levels, which was restored in cells expressing 
dominant negative PKC-δ or in PKC-δ knockout mice. Geral-
des et al. also identified SHP-1, a tyrosine kinase, as a cellular 
target of PKC-δ and p38α that inhibited the survival action of 
tyrosine kinase growth factor receptors such as PDGFR-β, by 
an NF-KB-independent pathway. Therefore, hyperglycemia 
induces activation of PKC-δ - p38α MAPK – SHP-1, which 
leads to the inhibition of PDGF–related survival actions that 
cause pericyte apoptosis in diabetic retinopathy. This study has 
identified SHP-1 as a new potential therapeutic target, to be in-
hibited as a treatment for diabetic vascular complications.
  Another survival factor is VEGF, which is one of the most 
important endogenous angiogenic polypeptides that respond 
to hypoxia under normal physiological conditions. The expres-
sion of VEGF is increased in the retina, causing diabetic pro-
liferative retinopathy; however, its abnormally low expression 
in the myocardium and peripheral lesions causes poor collat-
eral vessel formation in peripheral tissues. During angiogene-
sis, VEGF interacts with several other angiogenic factors, play-
ing an important role in cell proliferation, differentiation, mi-
gration, cell survival, NO production, release of other growth 
factors, and sympathetic innervation. VEGF may have actions 
in non-endothelial cells. VEGF is also produced by renal podo-
cytes. Podocytes and fenestrated endothelial cells are two ma-
jor cells of the glomerular filtration barrier. Mesangial cells are 
located between the capillary loops and provide structural 
support. The apoptosis of podocytes is an early event of dia-
betic nephropathy and a likely cause of proteinuria. Sison et al. 
[5] reported that VEGF-A released by podocytes was required 
for glomerular endothelial cell migration, differentiation, and 
survival through cell-specific gene targeting. The tyrosine ki-
nase receptors for VEGF (VEGFR-1 and VEGFR-2) were ex-
pressed by glomerular endothelial cells. Their podocyte-specif-
ic, heterozygous, conditional knock out of VEGF-A mice 
showed a loss of endothelial cell fenestrations, endothelial cell 
necrosis, loss of podocyte foot process, and a marked loss of 
mesangial cells. This suggests that the paracrine effects of VEGF 
are crucial for glomerulus development and maintaining the 
function of the glomerular filtration barrier. 
  Microalbuminuria is an early detectable clinical abnormali-
ty in diabetic glomerulopathy. Metabolic pathways activated 
by hyperglycemia, glycated proteins, hemodynamic factors, 
and oxidative stress are key players in the pathogenesis of dia-
betic nephropathy. A variety of growth factors and cytokines 
are then induced through complex signal transduction path-
ways. Podocyte-derived VEGF is an angiogenic factor whose 
expression is increased in animal models of diabetic kidney 
disease [6]. Controversies exist on the effect of the diabetes-
induced enhanced expression of VEGF in the renal glomeruli. 
Some have suggested that VEGFs act in a novel autocrine sig-
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Fig. 1.  Diabetes induces an imbalance between toxic and pro-
tective factors to cause complications. FFA, free fatty acid; 
AGE, advanced glycosylated end product; ROS, reactive oxy-
gen species; PKC, protein kinase C; PDGF, platelet-derived 
growth factor; VEGF, vascular endothelial growth factor; 
APC, activated protein C. Jeong I-K, et al.
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naling mode to induce the podocytopathy of diabetes, espe-
cially the genesis of albuminuria. Thus, treatment with anti-
VEGF antibodies may attenuate glomerular basement mem-
brane thickening and progression of diabetic nephropathy. 
However, recently Eremina et al. [7] reported proteinuria, hy-
pertension, and renal failure in several patients treated with 
anti-VEGF agent, bevacizumab. Pathologic findings from kid-
ney biopsies were prominent endothelial swelling, red cell 
fragments, mesangiolysis, and thrombi in capillary loops which 
were similar to those in podocyte-specific VEGF-A knockout 
mice. The study also suggested that anti-VEGF therapy inhib-
its the VEGF action of podocytes and results in endothelial 
damage and thrombotic microangiopathy.
  An alternative explanation is that the increased VEGF ex-
pression in the kidney is a compensatory action to protect the 
glomeruli from the toxic effects of hyperglycemia. This means 
that the increase of VEGF is a compensatory response to over-
come ischemic or other stressful injury which can induce VEGF 
resistance in the renal glomeruli by diabetes. 
  In contrast with diabetic microvascular complications, VEGF 
expression is reduced in diabetic heart and macrovasculature. 
Ventricular tissues from muscle insulin receptor knockout   
mice, which lack insulin receptors in the myocardium, have 
significant reductions in insulin but not IGF-I signaling, 
VEGF expression, and vascular density before and after isch-
emia versus controls [8]. This suggests that impaired insulin 
signaling has decreased VEGF expression and aggravated 
ischemic injury. Thus, VEGF is an important angiogenic and 
survival cytokine in protecting micro- and macro-vascular tis-
sues from conditions such as hyperglycemia. 
  Insulin is another important survival factor for vascular en-
dothelial cells. Insulin has been shown to have both anti-ath-
erosclerotic and pro-atherosclerotic actions in vascular cells. 
The anti-atherosclerotic actions of insulin include decreased 
endothelial cell apoptosis and reactive oxygen species, and in-
creased NO by activation of endothelial NO synthase and 
heme oxygenase-1. In contrast, insulin has also been reported 
to have pro-atherosclerotic actions such as increasing endo-
thelin-1 and plasminogen activator inhibitor-1, and enhanc-
ing the migration and growth of vascular smooth muscle cells. 
In diabetes, hyperglycemia can selectively inhibit insulin’s an-
ti-atherosclerotic actions, while hyperinsulinemia, as observed 
in insulin-resistant type 2 diabetes mellitus, can enhance insu-
lin’s pro-atherosclerotic effects to accelerate the prevalence of 
atherosclerotic diseases [9]. Rask-Madsen et al. [10] recently 
reported that loss of insulin signaling in endothelial cells ac-
celerated atherosclerosis in apolipoprotein E-null mice. Dou-
ble knockout mice with a deletion of the endothelial insulin 
receptor and apolipoprotein E gene (EIRAKO) were created 
using the Cre/loxP system to achieve tissue-specific deletion 
of these genes. Despite retaining systemic insulin sensitivity, 
glucose tolerance, plasma lipids, and blood pressure were not 
different between the EIRAKO and control mice; however, 
more severe atherosclerotic lesions, impaired vasodilatation, 
and increased VCAM-1 expression were observed in the EI-
RAKO mice vs. the apolipoprotein E-null mice. Therefore, im-
proving insulin sensitivity in the endothelium may decrease 
the risk for atherosclerosis in insulin resistance and diabetes 
states.
  Clinical evidences are also available in support of the impor-
tance of endogenous protective factors. Recently, we reported 
that a significant number of type 1 diabetes mellitus patients 
with a duration of diabetes of 50 years or longer do not have 
significant retinopathy and nephropathy (Joslin Medalist Study) 
[11]. This study demonstrated a lack of association between 
degree of hyperglycemia and prevalence of microvascular 
complications, although as a group, glycemic control in the 
study participants is very good, with a mean HbA1c of 7.3%. 
These results suggest that unknown endogenous protective 
factors are greatly reducing microvascular complications in 
this group of type 1 diabetic subjects of extremely long dura-
tion. If the protective factors could be found from the study of 
these patients, we may be able to prevent or delay microvascu-
lar complications in all diabetic patients.
  In summary, new therapeutic approaches for diabetic vas-
cular complications need to focus on decreasing the toxic fac-
tors of diabetes, but also need to focus on increasing the action 
of protective factors. 
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